intention to treat analysis

(redirected from intent to treat analysis)

intention to treat analysis

An analysis in which all trial participants are analysed according to the intervention to which they were allocated, whether they received that therapy or not. Such analyses are favoured in assessing effectiveness, as they mirror non-compliance and treatment changes likely to occur when the intervention is used in practice, and because of the risk of attrition bias when participants are excluded from the analysis.

intention to treat analysis

, intent to treat analysis
A clinical trial in which results from all randomized patients are included whether or not they actively participated in the complete study.
References in periodicals archive ?
An intent to treat analysis was performed by including vital status information (i.
Intent to treat analysis showed that the mean change from baseline in viral load at week 48 was -0.
Observed cases analysis using data on completers-a cherry-picked population-will almost inevitably have more positive results than an intent to treat analysis of all patients, including scores of dropouts at the time of attrition (last observation carried forward, or LOCF).
By intent to treat analysis at 48 weeks, 47% of patients in group C (quadruple therapy) had viral loads less than 50 copies/mL compared to 42%, 38% and 26% for groups A, B and D, respectively.
A subject is valid for per protocol analysis, if the subject: is (1) valid for modified intent to treat analysis and (2) has an adequate assessment of VTE that was done not later than a pre-defined period after stop of study drug (to be determined prior to unblinding and documented) and (3) met the inclusion criteria regarding medical illness and VTE risk factors and (4) shows no major protocol deviations.
The intent to treat analysis remains the same, with 63% of patients achieving ACR20.
In a modified intent to treat analysis which included all patients with at least one evaluable study radiograph and a minimum of one dose of study drug or placebo, toremifene citrate 80 mg demonstrated a 50% reduction in morphometric vertebral fractures (p<0.
The intent to treat analysis showed a delay in time to disease progression (p=0.
At 24-weeks, in an intent to treat analysis, 68 percent (112/164) of patients on Ziagen/Combivir had VL <400 copies/ml, compared to 57 percent (94/166) on the PI-containing regimen.